Agency's Preclusionary (And Erroneous) "Revolving Door" Advice Provides Pre-Award Bid Protest Standing
Client Alert | 1 min read | 05.09.08
In The CNA Corporation v. United States (April 30, 2008)
the COFC granted standing to a potential bidder arguing that it would be effectively disqualified from a procurement because a key employee, a former NIH scientist, had received an agency ethics opinion finding applicable the life-long representational ban under criminal statute 18 U.S.C. 207(a)(1), thus precluding her from being assigned to the contract. In finding for the protester, the COFC held that (1) the agency's 15-page legal opinion was wrong because it misapplied the definition of "personal and substantial participation" required to trigger the life-long representational ban, and, further, (2) even if the agency's ethics opinion had been correct as to a representational ban, the scope of prohibited "representation" under the statute was not as broad as the agency's interpretation and the protester would have been able to use the former NIH employee as its principal investigator were it awarded the contract.
Insights
Client Alert | 4 min read | 09.16.26
CMS Offers Guidance as Scrutiny Rises Over ABA Therapy in Medicaid
Between 2021 and 2025, Medicaid spending on ABA therapy grew six times faster than the number of children who received services, making it one of the fastest-growing areas of Medicaid expenditure, according to CMS. On August 4, 2026, CMS released a toolkit to help state Medicaid and CHIP agencies strengthen their programs and limit fraud, waste, and abuse tied to increased demand for ABA therapy. In 2025, Medicaid spent about $10 billion on ABA and related therapy services for children with ASD — a dramatic increase from the $2 billion spent in 2021.
Client Alert | 4 min read | 09.15.26
GAO Indicates Reasonable Conflict of Interest Investigation Must Include Inquiry of Involved Firm
Client Alert | 3 min read | 09.15.26
Client Alert | 7 min read | 09.14.26
AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development
